Macitentan-d4
Code | Size | Price |
---|
TAR-T11934-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T11934-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Macitentan D4 (ACT-064992 D4) is a deuterium labeled Sulfamethoxazole. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist.
CAS:
1258428-05-5
Formula:
C19H20Br2N6O4S
Molecular Weight:
592.3
Purity:
0.98
SMILES:
N(S(NCCC)(=O)=O)C=1C(=C(OC(C(OC=2N=CC(Br)=CN2)([2H])[2H])([2H])[2H])N=CN1)C3=CC=C(Br)C=C3
References
Corallo C, et al. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Res Ther. 2016 Oct 6;18(1):228.